Article Link: FDA Approves Beovu (brolucizumab-dbll) for the Treatment of Wet Age-Related Macular Degeneration (AMD) EAST HANOVER, N.J., ...
FDA Approves Scenesse (afamelanotide) for Erythropoietic Protoporphyria
Article Link: FDA Approves Scenesse (afamelanotide) for Erythropoietic Protoporphyria October 08, 2019 — The U.S. Food and Drug Adm...
FDA Approves Scenesse (afamelanotide) for Prevention of Phototoxicity in Erythropoietic Protoporphyria
Article Link: FDA Approves Scenesse (afamelanotide) for Prevention of Phototoxicity in Erythropoietic Protoporphyria October 08, 2019 ...
FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis
Article Link: FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American...
FDA Approves Aklief (trifarotene) Cream, a New Topical Retinoid for the Treatment of Acne
Article Link: FDA Approves Aklief (trifarotene) Cream, a New Topical Retinoid for the Treatment of Acne FORT WORTH, Texas – (October 4, 2...
FDA Approves Fasenra Pen (benralizumab) Pre-Filled Auto-Injector for Self-Administration
Article Link: FDA Approves Fasenra Pen (benralizumab) Pre-Filled Auto-Injector for Self-Administration October 4, 2019 — AstraZenec...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
Article Link: FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP) FOSTER CITY, Calif.&...
FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) in Pediatric Patients 6 Months of Age and Older
Article Link: FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) in Pediatric Patients 6 Months o...
FDA Approves Invokana (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes and DKD
Article Link: FDA Approves Invokana (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in...
FDA Approves Rituxan (rituximab) for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children
Article Link: FDA Approves Rituxan (rituximab) for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children ...
